Harel Insurance Investments & Financial Services Ltd. Raises Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 197,885.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,055,547 shares of the company's stock after purchasing an additional 22,044,407 shares during the period. Teva Pharmaceutical Industries comprises about 4.4% of Harel Insurance Investments & Financial Services Ltd.'s holdings, making the stock its 5th largest holding. Harel Insurance Investments & Financial Services Ltd. owned about 1.95% of Teva Pharmaceutical Industries worth $338,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $44,000. Golden State Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $39,000. Compagnie Lombard Odier SCmA acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $54,000. Finally, IFP Advisors Inc increased its position in Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Insiders Place Their Bets

In other news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.49% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TEVA shares. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA remained flat at $17.05 during midday trading on Friday. The stock had a trading volume of 5,550,481 shares, compared to its average volume of 10,266,065. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The stock has a fifty day moving average of $16.99 and a 200 day moving average of $17.37. The firm has a market capitalization of $19.56 billion, a price-to-earnings ratio of -14.83, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.48 earnings per share. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.